INVESTOR RELATIONS

Dr. Jim Deller

Director

Dr. Deller joined ClearSign Technologies as our President in February 2019, transitioned to Chief Executive Officer on April 1, 2019 and was appointed as a director on February 13, 2020. Dr. Deller began his career at Hamworthy Combustion while also completing his Ph.D. In 1996, Dr. Deller joined Callidus, where he was employed in Project Engineering and Sales, and over the course of ten years advanced to serve as Chief Combustion Engineer and Manager of Burner Order Execution before being promoted to oversee Callidus’ entire burner business. From 2010 until he left Callidus, following the acquisition of Callidus by Honeywell, Dr. Deller served as General Manager with full profit and loss accountability for the Honeywell UOP Callidus burner business worldwide. During that time, he led his team in developing new international markets, including developing a leading market position in China. From May 2018 until he joined the Company, Dr. Deller served as the interim Global Operations Director for the entire Honeywell International UOP Callidus business, which includes flares and thermal oxidizers in addition to burners. Dr. Deller provides technical and operational expertise to our board which is instrumental in ClearSign Technologies achieving our goals of proving commercial viability of our products, generating interest from end users and original equipment manufacturers and licensing our technology.

G. Todd Silva

Director

Mr. Silva joined the Board of Directors in August 2024. Mr. Silva brings over 30 years of leadership and finance experience in industries spanning industrials, financial services, technology, media, health care and others. Mr. Silva is the Chief Financial Officer of Radiance Therapeutics, Inc., an ophthalmic medical device company. Prior to his current role, Mr. Silva served as the Chief Financial Officer of Point Pickup Technologies, Inc., a logistics platform service where he worked to consummate and integrate acquisitions, raise capital through various private transactions and assist with corporate governance tasks for their board of directors. Additionally, Mr. Silva was the founder and director of Silva Partnership & Co., a firm providing corporate advisory services to early-stage technology businesses. Prior to Silva Partnership & Co., Mr. Silva was the executive director of corporate advisory services at Las Olas Capital Partners, a registered investment advisor firm where he advised a variety of companies on mergers and acquisitions, capital raises, recapitalizations and the launch of special purpose vehicles to invest in corporate and real estate transactions. Mr. Silva spent the earlier part of his career as a founder, portfolio manager, and research analyst in the institutional investment management industry in New York. Mr. Silva holds an MBA from Columbia University and a BS in economics and finance from Lehigh University.

Anthony DiGiandomenico

Director

Anthony DiGiandomenico joined the Board of Directors in May 2025. Mr. DiGiandomenico has been working with and enabling investment into early-stage disruptive technologies for most of his career. He has worked alongside a wide range of companies in biotechnology, medical devices, high technology, and renewable energy spaces. Mr. DiGiandomenico currently serves as the Chief of Transactions and director of MDB Capital Holdings, LLC (NASDAQ: MDBH), a broker-dealer and financial advisory firm based in Dallas, Texas, which he co-founded in 1997 as MDB Capital Group, LLC. Previously, he has served on the board of directors of Provention Bio, Inc., a developer of multiple drug therapies, from January 2017 until May 2020 and the board of directors of Cue Biopharma, Inc., a company that develops novel biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders, from January 2016 to October 2019. Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a B.S. in Finance from the University of Colorado.

Lou Basenese

Director

Lou Basenese joined the Board of Directors in May 2025. Mr. Basenese has over 25 years of experience in equity research and analysis, investment banking, strategic planning, thought leadership development and communications. Mr. Basenese currently serves as Executive Vice President – Market Strategy for Prairie Operating Co. (Nasdaq: PROP), a Houston-based publicly traded independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. He also serves as CEO and Chief Strategist of The Basenese Group, LLC, a full-service equity research, strategy, and advisory firm. Mr. Basenese also serves on the board of directors of ENDRA Life Sciences, Inc. (Nasdaq: NDRA), a life sciences company that develops technologies to improve the capabilities of clinical diagnostic ultrasound, and the board of directors of The Roberto Clemente Health Clinic, a U.S.-based non-profit that provides affordable access to high quality health care and wellness programs in the Tola coastal communities of Nicaragua. Prior to his current roles, Mr. Basenese served as President and Chief Market Strategist of MDB Capital Holdings, LLC (Nasdaq: MDBH) and in various analyst, strategist, and account executive roles in the financial services and research industries. Mr. Basenese holds an MBA from the Crummer Graduate School of Business at Rollins College and a B.A. in English from the University of Florida.